Skip to content

Monitoring of Core body temperature, Heart rate (HR) and Respiration rate (RR)

Bravo1 Patient Monitor (PM) Platform: Core Body Temperature, Heart Rate and Respiration Rate Validation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/08/044885
Enrollment
105
Registered
2022-08-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 4- Measurement and Monitoring

Interventions

Intervention1: NIL: NIL

Sponsors

BraveHeart Wireless Inc BHW
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •All subjects shall be at least 18 years or older. •In good general health without any evidence of medical issues and/or problems. •The subject must have the ability to understand and provide written informed consent. •The subject must be willing and able to comply with study procedures and duration. •Male or female of any race but a wide demographic across age, gender and race is preferred. •It is required, by ISO 80601-2-56, that 30% - 50% of subjects shall be recruited that demonstrate as febrile from the population of all subjects identified for the study. •A febrile subject is someone having: â?ª An elevated core temperature of 38.0 Dec C (100.4 Deg F) or higher as measure by the Reference Clinical Thermometer (RCT). â?ª An elevated sublingual temperature of 37.5 Deg C (99.5 Deg F) or higher as measured by the RCT, or â?ª An elevated axillary temperature of 37.2 Deg C (99.0 Deg F) or higher as measured by the RCT.

Exclusion criteria

Exclusion criteria: •The subject is a current smoker •The subject is pregnant, lactating or trying to get pregnant. •The subject has a known history of heart disease, lung disease, kidney or liver disease. •Diagnosis of asthma, sleep apnea, or use of CPAP. •Diagnosed or self-reported respiratory diseases/impairment. •Diagnosed or self-reported cardiovascular diseases/impairment. •Subjects with inflammation at the measuring site. •Subjects that have taken antipyretics in the preceding 120 min. •Subjects meeting contraindications for device •Subjects showing inflammation or skin damage at the measuring site (i.e., if site selection has open wounds, erythema, redness, old scar/wounds) •Subjects with known skin allergies (e.g., silicone or hydrocolloid adhesives and/or hydrogel) •The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with the study procedures. •The subject has any other condition, which in the opinion of the investigators would make them unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
â?¢ Respiration Rate Data collected on the ML Explorer app. â?¢ HR data collected on the ML Explorer App. â?¢ Core body Temperature Data recorded from the reference clinical thermometer (RCT) as noted against the Bravo1 PM Platform skin temperature results. â?¢ Respiration Rate Data collected with the CapnosteamTM20p Portable Bedside Monitor Capnograph. â?¢ Multi-modality bio signals (PPG, temperature, motion) collected with ADI Fenda and SpO2 watches. Timepoint: 1.5 Hours

Secondary

MeasureTime frame
â?¢ Respiration Rate Data collected on the ML Explorer app. â?¢ HR data collected on the ML Explorer App. â?¢ Core body Temperature Data recorded from the reference clinical thermometer (RCT) as noted against the Bravo1 PM Platform skin temperature results. â?¢ Respiration Rate Data collected with the CapnosteamTM20p Portable Bedside Monitor Capnograph. â?¢ Multi-modality bio signals (PPG, temperature, motion) collected with ADI Fenda and SpO2 watches. Timepoint: 1.5 Hours

Countries

India

Contacts

Public ContactDr K Naresh Chandra
drvenkateshwarraoavula@gmail.com9440040662

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026